1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Pfizer’s Biosimilars Grow By A Tenth

As First-Half Sales Of Sterile Injectables Slip By A Similar Proportion

 
• By Dave Wallace

Pfizer has reported healthy growth of a tenth for its biosimilars portfolio in the first half of 2022, at the same time as its sterile injectables sales slipped by a similar degree.

Pfizer logo
Pfizer has seen biosimilars grow and sterile injectables decline in the first half of 2022 • Source: Alamy

Pfizer’s biosimilars sales grew by a tenth to $1.19bn in the first half of 2022, the company has reported, having already benefited from enormous growth in 2021 when the firm’s full-year turnover from biosimilars grew by 53% to $2.34bn. (Also see "Pfizer’s Biosimilars Top $2.3bn In 2021" - Generics Bulletin, 21 February, 2022.)

Much of Pfizer’s first-half biosimilars growth was driven by the US market, where biosimilars sales were up by 21% to $837m. This offset an aggregate drop of 13% to $348m in the rest of the world, entirely due to a fall of 30% to $209m for biosimilars in developed Europe

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”